Baxter International weekly move, shares lag key healthcare peers

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 10:13.

Baxter International (US0673431090) starts the end of the week trading on the NYSE with shares in the low 20-dollar range, below many diversified healthcare peers. The stock’s current level highlights a marked valuation gap versus large-cap medtech names such as Medtronic and Becton Dickinson, which investors are watching in the broader S&P 500 healthcare cohort.

How Baxter compares in healthcare

On recent sector data, Baxter International shares traded around 21.55 dollars in the latest session, based on a June 25 closing snapshot from a forecasting platform that tracks NYSE-listed stocks. This level leaves Baxter well under the typical price band for larger medtech and supplies peers, with many comparable US healthcare names changing hands at significantly higher nominal prices.

In the broader peer set, Medtronic and Becton Dickinson both occupy higher market-cap tiers and command more robust valuations, reflecting diversified portfolios in devices and diagnostics alongside scale advantages. Baxter’s current share price near the low twenties underscores how the market is still pricing in restructuring efforts and portfolio simplification that the company has pursued in recent years, positioning it differently from some higher-rated S&P 500 healthcare constituents.

Sector performance and consensus context

Across the industry, healthcare and medtech names have shown mixed year-to-date performance, with investors balancing defensive earnings profiles against pricing scrutiny and capital allocation questions. Baxter’s latest indicated analyst fair value around 21.54 dollars, effectively in line with its current trading zone, suggests a muted near-term upside view from some quantitative consensus models that track the stock.

For shorter-term projections, one model points to a modest target price of about 21.57 dollars for early July, implying steady rather than aggressive expected movement. This near-flat forecast contrasts with more dynamic expectations for some high-growth healthcare technology and life-science tools names which have benefitted from stronger revenue momentum and higher market multiples in 2026, reinforcing the perception that Baxter is in a consolidation phase relative to more expansionary sector peers.

How Baxter generates its revenue

Baxter International’s business model centers on supplying hospitals and clinics with critical-care and renal products, infusion systems and related pharmaceuticals. A representative offering is its portfolio of intravenous (IV) solutions, including standard saline and specialized fluids used globally in acute-care settings, which anchor recurring revenue streams across multiple regions.

Where Baxter shares trade now

The Baxter International shares (US0673431090) recently traded on the NYSE around 21.55 dollars on June 25, 2026, based on external quote data, illustrating the current valuation investors apply to the company in the US healthcare sector.

This text is for informational purposes only and does not constitute investment advice, tax advice or a solicitation to buy or sell securities. Figures and assessments are based on sources believed to be reliable at the time of publication but may change without notice.